Latest / Stock Movers / NextEra to Buy Dominion; Ryanair Rallies; Regeneron Drops on Disappointing Data
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 1: Let's take a look at some stocks on the move today.
- 0:19Speaker 1: I'm Tim Keen with Bol Sweeny and Bloomberg's Alexis Christopher.
- 0:23Speaker 3: And it is a thing of beauty because we're going
- 0:24Speaker 3: to start with a big deal not only for the
- 0:27Speaker 3: day or the week, possibly the year. It's in the
- 0:30Speaker 3: energy sector, Next Era Energy buying Dominion Energy. This is
- 0:35Speaker 3: a roughly sixty seven billion dollar deal in stock, the
- 0:39Speaker 3: equivalent around seventy six dollars a share to Dominion shareholders
- 0:42Speaker 3: based on Friday's closing price. In addition, they will receive
- 0:45Speaker 3: a one time cash payment of three hundred and sixty
- 0:48Speaker 3: million dollars once this deal closes, which they expect to
- 0:51Speaker 3: have happen in about a year and a half. So
- 0:54Speaker 3: this deal is going to combine two of the largest
- 0:56Speaker 3: US utilities into an East Coast Titan territories in Florida,
- 1:02Speaker 3: the Carolinas, Virginia. So this is going to require statement
- 1:07Speaker 3: federal regulators to sign off on it though, But the
- 1:09Speaker 3: stock is up big time to Minion up fifteen percent
- 1:12Speaker 3: here on this news today. It was already up five
- 1:14Speaker 3: percent year to.
- 1:14Speaker 1: Take seventy what's surprise.
- 1:16Speaker 3: Seventy seventy six a share.
- 1:18Speaker 1: I'm interpolating this. Don't hold me to this, folks, But Paul,
- 1:22Speaker 1: you know, dominion is what every grandmother owned, right, Yes,
- 1:25Speaker 1: I mean it's all there is to it. You ready,
- 1:28Speaker 1: three point three percent per year for the last ten years.
- 1:32Speaker 2: Yeah, she had a dividend out.
- 1:34Speaker 1: Yeah, that includes dividend wise statistic without I'm sorry, it's
- 1:39Speaker 1: it's just it's unacceptable.
- 1:41Speaker 3: Next, all right, Ryan Air, So it's trading over in
- 1:45Speaker 3: Dublin up four percent. It was down twenty two percent
- 1:48Speaker 3: year to date ahead of this news. So Ryanair CEO
- 1:51Speaker 3: saying he has quote almost zero concerns about its jet
- 1:55Speaker 3: fuel supplies this summer. And this is of course in
- 1:58Speaker 3: midfears of widespread cancelations in the airline industry linked to
- 2:03Speaker 3: the high fuel costs in the war with Iran. The
- 2:06Speaker 3: CEO says, uncertainty though, is making traveler's book. Later, he
- 2:10Speaker 3: says that's actually keeping summer holiday fairs down because the
- 2:13Speaker 3: demand just isn't isn't there. He said that Europe is
- 2:16Speaker 3: now well stocked with fuel, and he says that's thanks
- 2:19Speaker 3: to shipments from West Africa, Norway and the Americas. Ryanair
- 2:23Speaker 3: has hedged eighty percent of its jet fuel requirements out
- 2:27Speaker 3: until April of next year, at about sixty seven dollars
- 2:30Speaker 3: a barrel. But he said, if this war continues and
- 2:32Speaker 3: goes on for another like year, let's say, and we have,
- 2:35Speaker 3: oh my goodness, you have oil prices continuing to stay high.
- 2:38Speaker 3: He believes we're going to see some low cost airlines
- 2:40Speaker 3: in Europe go bust, sort of a Las Spirit airlines. Okay,
- 2:44Speaker 3: that's good for Ryan, Yeah, Ryan Air. Yeah, I mentioned right,
- 2:46Speaker 3: us up four percent. It wasn't It was lower earlier today,
- 2:49Speaker 3: but then it did a little turnaround, all right, and
- 2:51Speaker 3: then we've got Regeneron. So this is a biopharma company
- 2:55Speaker 3: down twelve percent. It was already down nine and a
- 2:58Speaker 3: half percent year to date. So it's late stage trial
- 3:01Speaker 3: for the skin for a skin cancer treatment treatment missed
- 3:05Speaker 3: its main goal. So the drug did not show a
- 3:08Speaker 3: statistically significant improvement and progression free survival. Basically, it means
- 3:13Speaker 3: it didn't delay disease progression or death. H and Wall
- 3:17Speaker 3: Street answered back with a number of downgrades. Also, price
- 3:21Speaker 3: targets being lowered today on the stock and Regeneron had
- 3:24Speaker 3: already been going through it because this comes after another
- 3:28Speaker 3: drug failed uh, you know tests last year, so investors
- 3:32Speaker 3: are growing impatient with Regeneron.
- 3:35Speaker 2: The stock mover's report from Bloomberg Radio. Check back with
- 3:40Speaker 2: us throughout the day for the latest roundup of companies
- 3:42Speaker 2: making news on Wall Street and for the latest market
- 3:45Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:50Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:53Speaker 2: the Bloomberg Business app.